IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.47 USD
-0.01 (-1.35%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $0.45 -0.02 (-3.85%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for IGC Pharma, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 3 | 10 | 15 | 12 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 3 | 4 | 5 | 4 |
Other Current Assets | 1 | 0 | 1 | 3 | 1 |
Total Current Assets | 4 | 6 | 15 | 24 | 18 |
Net Property & Equipment | 4 | 8 | 9 | 11 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 1 | 1 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 10 | 17 | 27 | 36 | 29 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 2 | 3 | 3 | 2 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 124 | 119 | 116 | 110 | 95 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -114 | -101 | -89 | -74 | -65 |
Other Equity | -3 | -3 | -3 | -3 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 15 | 24 | 33 | 27 |
Total Liabilities & Shareholder's Equity | 10 | 17 | 27 | 36 | 29 |
Total Common Equity | 7 | 15 | 24 | 33 | 27 |
Shares Outstanding | 66.80 | 53.00 | 51.00 | 45.30 | 39.30 |
Book Value Per Share | 0.11 | 0.28 | 0.47 | 0.72 | 0.68 |
Fiscal Year End for IGC Pharma, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 1 | 3 | 2 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2 | 2 | 3 | 3 |
Other Current Assets | NA | 1 | 0 | 0 | 0 |
Total Current Assets | NA | 4 | 4 | 6 | 5 |
Net Property & Equipment | NA | 4 | 5 | 8 | 8 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 1 | 1 | 1 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 10 | 11 | 17 | 16 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 1 | 2 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 2 | 2 | 2 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3 | 2 | 2 | 2 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 124 | 123 | 123 | 119 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -114 | -111 | -105 | -103 |
Other Equity | NA | -3 | -3 | -3 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 7 | 9 | 14 | 13 |
Total Liabilities & Shareholder's Equity | NA | 10 | 11 | 17 | 16 |
Total Common Equity | 0 | 7 | 9 | 14 | 13 |
Shares Outstanding | 75.60 | 66.80 | 63.70 | 53.70 | 53.90 |
Book Value Per Share | 0.00 | 0.11 | 0.14 | 0.26 | 0.24 |